logo

Immunomedics Inc. (IMMU)



Trade IMMU now with
  Date
  Headline
11/7/2018 4:04:15 PM Immunomedics Expands Clinical Collaboration With Astrazeneca To Include Metastatic Non-Small Cell Lung Cancer
8/23/2018 4:12:19 PM Immunomedics Q4 Loss/share $0.68 Vs. Loss $0.48 Year Ago
7/30/2018 8:08:07 AM Immunomedics Reports Multiple Clinical And Preclinical Collaborations With Prominent Cancer Research Institutions
7/18/2018 8:08:10 AM FDA Accepts BLA For Filing And Grants Priority Review For Sacituzumab Govitecan For MTNBC
6/15/2018 11:47:59 AM Immunomedics Announces Closing Of Public Offering Of Common Stock
6/13/2018 8:04:05 AM Immunomedics Prices Underwritten Public Offering Of 11.5 Mln Shares At $24/shr For Gross Proceeds Of About $276 Mln
6/3/2018 11:09:06 AM Immunomedics Announces Results From Phase 1/2 Study Of Its Lead Investigational ADC
6/1/2018 8:09:50 AM Immunomedics Announces Pivotal Study Of Sacituzumab Govitecan In Patients With Locally Advanced Or MUC
5/21/2018 8:10:40 AM Immunomedics Submits BLA For Sacituzumab Govitecan To FDA
4/9/2018 8:05:14 AM Immunomedics Appoints Robert Iannone Head Of Research & Development And Chief Medical Officer
1/8/2018 8:37:02 AM Immunomedics, Royalty Pharma Announce Royalty Funding And Stock Purchase Agreements Totalling $250 Mln